Senate unanimously passes bill creating prescription drug affordability board with confidentiality and conflict safeguards

The Louisiana Senate on April 14 approved Senate Bill 401 to establish a Prescription Drug Affordability Board housed in the Department of Insurance. Sponsor Senator Talbot described the board’s purpose as studying prescription drug costs, identifying outliers and recommending remedies for unaffordable pricing.

During floor consideration the sponsor worked with manufacturers and stakeholders to adopt a suite of amendments that addressed major industry concerns and strengthened procedural safeguards. One amendment instructs the Department of Insurance to handle and protect proprietary information submitted to the board and to determine what must remain confidential. Other adopted changes create thresholds to limit routine review of generics (generics or biosimilars may be placed on the board’s list only if unit cost is $100 or more or their price rises by 200% in 12 months), add a patient‑advocacy appointee to the board, and bar membership by employees, consultants or designees with current financial ties to manufacturers, PBMs or carriers.

Sponsor Talbot said those negotiated changes responded to concerns raised during testimony and preserved necessary industry protections without undermining the board’s ability to study high‑cost brand drugs. "We want to make sure proprietary information is handled appropriately," the sponsor said while describing the confidentiality mechanism.

The Senate adopted the amendments and voted to pass the bill on third and final reading. Backers framed SB 401 as an investigatory and policy‑analysis body rather than a price‑setting authority; it is designed to generate findings that other actors — the legislature, regulators or payers — could use.

What’s next: With final passage on the Senate floor, SB 401 moves to the House for companion consideration (or reconciliation if the House has separate changes). The bill includes specific instructions on data handling and conflict‑of‑interest safeguards as adopted on the floor.